antiviral news

Press Releases in the global landscape

Dec 17, 2025

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

Ratutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds.

Dec 16, 2025

Paxlovid linked to fewer lost workdays, disability claims in employees at high-risk for severe COVID

Employees who took the antiviral drug had 5% fewer workday absences.

Dec 10, 2025

Dear Doctor: Was my doctor off base when he told me Paxlovid cures COVID, so I don’t need to be vaccinated

A medical advice column clarifies that COVID-19 prevention through vaccination is superior to treatment alone, countering misconceptions about antiviral drugs replacing vaccines.

Dec 8, 2025

Older chemical libraries yield new leads for next-generation COVID-19 antivirals

SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.

Nov 13, 2025

Hot Takes from IDWeek: CDC, COVID, and Two Doses of Dalbavancin

Commentary from IDWeek discussing CDC topics, COVID, and dalbavancin dosing.

Nov 10, 2025

Greater benefits of immediate nirmatrelvir-ritonavir initiation for post-COVID outcomes: a population-based retrospective cohort study

A population-based cohort study showed that early use of nirmatrelvir-ritonavir significantly improved long-term post-COVID outcomes.